1. Scrip
  3. >>Clinical Trials

Oculis’s OCS-01 Sparkles Treating Front-Of-Eye Inflammation

Swiss Biotech To Now Talk With FDA On Two Phase III Designs

 
• By Sten Stovall

Oculis’s eyedrop OCS-01 showed high efficacy treating post-cataract inflammation in front of the eye, adding to its effective use in back-of-the-eye conditions.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
Positive Phase II front-of-the-eye data builds on good back-of-eye disease results. • Source: Shutterstock

With two successful Phase II programs in hand for its lead ocular therapy, Swiss biotech Oculis will now engage with the US Food and Drug Administration to agree a path forward and the design of pivotal studies assessing its daily OCS-01 eyedrop as a treatment for both inflammation and pain following cataract surgery as well as for diabetic macular edema (DME).

OCS-01 is a proprietary nanoparticle formulation of the steroid dexamethasone, that has been designed as a topical treatment for ocular inflammation and has particular benefits over injections or implants that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D